BLUEPRINT MEDICINES CORP (BPMC)
US09627Y1091 - Common Stock
BPMC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 570 industry peers in the Biotechnology industry. Both the profitability and financial health of BPMC have multiple concerns. BPMC is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
BPMC had negative earnings in the past year.
BPMC had a negative operating cash flow in the past year.
In the past 5 years BPMC reported 4 times negative net income.
In the past 5 years BPMC reported 4 times negative operating cash flow.
1.2 Ratios
BPMC's Return On Assets of -10.67% is amongst the best of the industry. BPMC outperforms 87.13% of its industry peers.
Looking at the Return On Equity, with a value of -40.89%, BPMC is in the better half of the industry, outperforming 73.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.67% | ||
| ROE | -40.89% | ||
| ROIC | N/A |
ROA(3y)-47.02%
ROA(5y)-34.38%
ROE(3y)-187.61%
ROE(5y)-123.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 97.01%, BPMC belongs to the best of the industry, outperforming 97.00% of the companies in the same industry.
In the last couple of years the Gross Margin of BPMC has remained more or less at the same level.
BPMC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.14%
GM growth 5YN/A
2. Health
2.1 Basic Checks
BPMC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BPMC has been increased compared to 1 year ago.
Compared to 5 years ago, BPMC has more shares outstanding
The debt/assets ratio for BPMC is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.60, we must say that BPMC is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.60, BPMC is doing good in the industry, outperforming 68.61% of the companies in the same industry.
A Debt/Equity ratio of 1.09 is on the high side and indicates that BPMC has dependencies on debt financing.
BPMC's Debt to Equity ratio of 1.09 is on the low side compared to the rest of the industry. BPMC is outperformed by 78.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.6 |
ROIC/WACCN/A
WACC10.69%
2.3 Liquidity
A Current Ratio of 3.32 indicates that BPMC has no problem at all paying its short term obligations.
BPMC has a worse Current ratio (3.32) than 60.32% of its industry peers.
BPMC has a Quick Ratio of 3.27. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BPMC (3.27) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.32 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 47.44% over the past year.
The Revenue has grown by 100.84% in the past year. This is a very strong growth!
BPMC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 41.16% yearly.
EPS 1Y (TTM)47.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.55%
Revenue 1Y (TTM)100.84%
Revenue growth 3Y-32.02%
Revenue growth 5Y41.16%
Sales Q2Q%126.61%
3.2 Future
The Earnings Per Share is expected to grow by 23.69% on average over the next years. This is a very strong growth
BPMC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.56% yearly.
EPS Next Y88.06%
EPS Next 2Y37.26%
EPS Next 3Y30.21%
EPS Next 5Y23.69%
Revenue Next Year107.83%
Revenue Next 2Y70.17%
Revenue Next 3Y56.65%
Revenue Next 5Y39.56%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BPMC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BPMC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BPMC's earnings are expected to grow with 30.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.26%
EPS Next 3Y30.21%
5. Dividend
5.1 Amount
BPMC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BLUEPRINT MEDICINES CORP
NASDAQ:BPMC (12/4/2024, 2:01:35 PM)
96.18
-0.35 (-0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.11B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.67% | ||
| ROE | -40.89% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.01% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.32 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)47.44%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y88.06%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)100.84%
Revenue growth 3Y-32.02%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y